Ipca Laboratories Limited Ipca Laboratories Limited

Ipca Laboratories Limited

IPCALAB

주식 순위 #3410
Ipca Laboratories Limited, an integrated pharmaceutical company, manufactures... Ipca Laboratories Limited, an integrated pharmaceutical company, manufactures and markets formulations and active pharmaceutical ingredients (APIs) for various therapeutic segments in India, Europe, Africa, the Americas, Asia, the Commonwealth of Independent States, and Australasia. The company offers APIs in anti-hypertensive, anti-malarial, diuretic, DMARD, anti-hypertensive, and anthelmintic therapeutic areas. It also provides generic and branded formulations in various therapeutic segments, including allergy, anti-neoplastic/cancer drugs, anti-arthritic, anti-epileptic, anti-hypertensive, cardiology, diabetes, dermatology, diabetology, emollients/protectives, fever, gastroenterology, helminthics, hepatoprotectives, immunosuppressant, infectious diseases, malaria, neurology, neuropathic pain, and NSAIDs, as well as nutraceuticals, ophthalmology, oral anti diabetes drug, orthopedics, probiotics, psychiatry, respiratory, rheumatology, and urology. The company also exports its products worldwide. Ipca Laboratories Limited was incorporated in 1949 and is based in Mumbai, India.
주가
$20.00
마지막 동기화: 2026-10-19
시가총액
$5.08B
변동 (1일)
-1.76%
변동 (1년)
38.31%
국가
IN
거래 Ipca Laboratories Limited (IPCALAB)

카테고리

Healthcare
Ipca Laboratories Limited (IPCALAB)의 수익
Jun 2026 기준 수익 TTM: $200.02M
Ipca Laboratories Limited의 최신 재무 보고서에 따르면 회사의 현재 수익은 $200.02M입니다. 2024년에 회사는 $100.31M의 수익을 올렸으며 이는 2023년의 수익 $89.11M과 증가입니다. 이 페이지에 표시된 수익은 이자 및 세금 공제 전 수익으로, 즉 EBIT입니다.
Ipca Laboratories Limited의 수익 기록 (2005 ~ 2026)
연말 수익
연도 수익 변화
2026 (TTM) $200.02M 51.54%
2025 $131.99M 31.59%
2024 $100.31M 12.56%
2023 $89.11M -39.31%
2022 $146.83M -22.19%
2021 $188.69M 92.38%
2020 $98.08M 24.63%
2019 $78.69M 76.36%
2018 $44.62M 10.42%
2017 $40.41M 135.71%
2016 $17.14M -69.96%
2015 $57.08M -45.77%
2014 $105.26M 26.12%
2013 $83.46M 16.17%
2012 $71.85M -6.02%
2011 $76.45M 28.95%
2010 $59.28M 154.37%
2009 $23.31M -46.79%
2008 $43.80M 23.03%
2007 $35.60M 112.82%
2006 $16.73M -22.39%
2005 $21.55M 0.00%
유사 기업 또는 경쟁사의 수익